慢性腎臓病治療薬の世界市場：薬剤クラス別、投与経路別、適応症別、流通チャネル別、地域別

世界の慢性腎臓病治療薬の市場規模は、2024年に151億米ドルに達し、2024～2031年にかけてCAGR 5.2％で成長し、2031年には215億5,000万米ドルに達すると予測されています。

図.慢性腎臓病治療薬市場シェア（%）、2024年地域別

世界の慢性腎臓病治療薬市場の成長を牽引するのは、世界の腎臓病有病率の上昇です。慢性腎臓病（CKD）とは、時間の経過とともに腎機能が徐々に低下することを指します。CKDを治療せずに放置すると、最終的に腎不全や末期腎疾患に至る可能性があります。CKDの一般的な原因には、糖尿病、高血圧、糸球体腎炎、多発性嚢胞腎などがあります。老年人口の増加や生活習慣病の増加は、CKDの有病率の増加につながる可能性があります。慢性腎臓病治療薬は、病気の進行を遅らせ、合併症を治療し、腎臓全体の健康を維持することを目的としています。レニンアンジオテンシン系阻害薬、カルシウム拮抗薬、赤血球造血刺激因子製剤、利尿薬などが、慢性腎臓病の管理に使用される主な薬剤クラスです。

市場力学：

世界の慢性腎臓病治療薬市場の成長は、糖尿病と高血圧の有病率の上昇によってもたらされます。国際糖尿病連合が発表したデータによると、2021年には全世界で約5億3,700万人の成人が糖尿病を患っています。この数は2030年には6億4,300万人、2045年には7億8,300万人に増加すると予測されています。高血圧もCKDの主な原因です。腎臓病の早期診断と治療に関する認識を広めるための政府の積極的な取り組みは、市場の成長を促進する可能性があります。しかし、新薬承認のための厳しい規制や、長期治療に伴う重篤な副作用のリスクが市場成長の妨げとなる可能性があります。併用療法や標的療法の開発は、慢性腎臓病治療薬産業のメーカーに有利な機会をもたらします。

本調査の主な特徴

本レポートでは、世界の慢性腎臓病治療薬市場を詳細に分析し、2023年を基準年とした予測期間（2024～2031年）の市場規模（10億米ドル）および複合年間成長率（CAGR%）を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。

また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。

世界の慢性腎臓病治療薬市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。

当レポートで取り上げられている主要企業は、Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Sanofi, Keryx Biopharmaceuticals, Kissei Pharmaceutical Co.Ltd.、AstraZeneca plc, Teva Pharmaceutical Industries Ltdが挙げられます。

本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

世界の慢性腎臓病治療薬市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。

利害関係者は、世界の慢性腎臓病治療薬市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 影響分析
• 主なハイライト
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• ポーターの分析
• 合併と買収のシナリオ

第4章 世界の慢性腎臓病治療薬市場、薬剤クラス別、2019～2031年（10億米ドル）

• ACE阻害薬
• アンジオテンシン受容体拮抗薬（ARB）
• Bブロッカー
• カルシウムチャネル遮断薬
• ループ利尿薬
• 赤血球造血刺激因子製剤（ESA）
• リン酸結合剤
• その他

第5章 世界の慢性腎臓病治療薬市場、投与経路別、2019～2031年（10億米ドル）

• 経口
• 非経口

第6章 世界の慢性腎臓病治療薬市場、適応症別、2019～2031年（10億米ドル）

• 糖尿病性腎症
• 糸球体腎炎
• 高血圧性腎症
• 多発性嚢胞腎
• その他の適応症

第7章 世界の慢性腎臓病治療薬市場、流通チャネル別、2019～2031年（10億米ドル）

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界の慢性腎臓病治療薬市場、地域別、2019～2031年（10億米ドル）

• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東

第9章 競合情勢

• AstraZeneca
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Sanofi
• GlaxoSmithKline plc（GSK）
• AbbVie Inc.
• Keryx Biopharmaceuticals, Inc.
• Kissei Pharmaceutical Co., Ltd.
• Regeneron Pharmaceuticals, Inc.
• Bayer AG
• Reata Pharmaceuticals, Inc.
• Ardelyx, Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Novartis AG
• Johnson & Johnson
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• Akebia Therapeutics, Inc.

第10章 アナリストの推奨事項

• 運命の輪
• アナリストの見解
• 一貫した機会マップ

第11章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Global chronic kidney disease drugs market is estimated to be valued at USD 15.10 Billion in 2024 and is expected to reach USD 21.55 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.

Figure. Chronic Kidney Disease Drugs Market Share (%), By Region 2024

Global chronic kidney disease drugs market h growth is driven by rising prevalence of kidney disorders worldwide. Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time. If left untreated, CKD can eventually lead to kidney failure or end-stage renal disease. Some of the common causes of CKD include diabetes, high blood pressure, glomerulonephritis, and polycystic kidney disease. Growing geriatric populations and increasing lifestyle diseases can lead to increased prevalence of CKD. The chronic kidney disease drugs aim to slow down the progression of the disease, treat complications, and help maintain overall kidney health. Renin-angiotensin system inhibitors, calcium channel blockers, erythropoiesis-stimulating agents, and diuretics are some of the major drug classes used for managing chronic kidney diseases.

Market Dynamics:

Global chronic kidney disease drugs market growth is driven by rising prevalence of diabetes and hypertension as both are significant risk factors for CKD. According to the data published by the International Diabetes Federation, nearly 537 million adults lived with diabetes in 2021 across the globe. This number is anticipated to rise to 643 million by 2030 and 783 million by 2045. High blood pressure, or hypertension, is also a major culprit for CKD cases. Favorable government initiatives to spread awareness about early diagnosis and treatment of kidney diseases can drive the market growth. However, stringent regulations for new drug approval and the risk of severe side effects associated with long-term therapy can hamper the market growth. The development of combinational and targeted therapies presents lucrative opportunities for manufacturers in the chronic kidney disease drugs industry.

Key features of the study:

This report provides in-depth analysis of the global chronic kidney disease drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic kidney disease drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Sanofi, Keryx Biopharmaceuticals, Kissei Pharmaceutical Co. Ltd., AstraZeneca plc, Teva Pharmaceutical Industries Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market

Detailed Segmentation-

• By Drug Class
  • ACE Inhibitors
  • Angiotensin Receptor Blockers (ARBs)
  • B-Blockers
  • Calcium Channel Blockers
  • Loop Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Phosphate Binders
  • Others
• By Route of Administration:
  • Oral
  • Parenteral
• By Indication
  • Diabetic Nephropathy
  • Glomerulonephritis
  • Hypertensive Nephropathy
  • Polycystic Kidney Disease
  • Other Indications
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Key Players Insights
  • AstraZeneca
  • Amgen Inc.
  • Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Sanofi
  • GlaxoSmithKline plc (GSK)
  • AbbVie Inc.
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Reata Pharmaceuticals, Inc.
  • Ardelyx, Inc.
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/S
  • Novartis AG
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Akebia Therapeutics, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Chronic Kidney Disease Drugs Market, By Drug Class
  • Global Chronic Kidney Disease Drugs Market, By Route of Administration
  • Global Chronic Kidney Disease Drugs Market, By Indication
  • Global Chronic Kidney Disease Drugs Market, By Distribution Channel
  • Global Chronic Kidney Disease Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• ACE Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Angiotensin Receptor Blockers (ARBs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• B-Blockers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Calcium Channel Blockers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Loop Diuretics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Erythropoiesis-Stimulating Agents (ESAs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Phosphate Binders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Chronic Kidney Disease Drugs Market, By Route of Administration, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Parentral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Chronic Kidney Disease Drugs Market, By Indication, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Diabetic Nephropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Glomerulonephritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Hypertensive Nephropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Polycystic Kidney Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Other Indications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Chronic Kidney Disease Drugs Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2019 - 2031, (USD Bn)
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Sanofi
• GlaxoSmithKline plc (GSK)
• AbbVie Inc.
• Keryx Biopharmaceuticals, Inc.
• Kissei Pharmaceutical Co., Ltd.
• Regeneron Pharmaceuticals, Inc.
• Bayer AG
• Reata Pharmaceuticals, Inc.
• Ardelyx, Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Novartis AG
• Johnson & Johnson
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• Akebia Therapeutics, Inc.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us